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Abstract 
AIM: This study aims to elucidate the possible ameliorative effect of silymarin on scopolamine-induced dementia 
using the object recognition test (ORT) in rats.  
METHODS: The study was extended to demonstrate the role of cholinergic activity, oxidative stress, 
neuroinflammation, brain neurotransmitters and histopathological changes in the anti-amnestic effect of silymarin 
in demented rats. Wistar rats were pre-treated with silymarin (200, 400, 800 mg/kg) or donepezil (10 mg/kg) orally 
for 14 consecutive days. Dementia was induced after the last drug administration by a single intraperitoneal dose 
of scopolamine (16 mg/kg). Then behavioural, biochemical, histopathological, and immunohistochemical analyses 
were then performed.  
RESULTS: Rats pre-treated with silymarin counteracted scopolamine-induced non-spatial working memory 
impairment in the ORT and decreased acetylcholinesterase (AChE) activity, reduced malondialdehyde (MDA), 
elevated reduced glutathione (GSH), restored gamma-aminobutyric acid (GABA) and dopamine (DA) contents in 
the cortical and hippocampal brain homogenates. Silymarin reversed scopolamine-induced histopathological 
changes. Immunohistochemical analysis showed that silymarin mitigated protein expression of the glial fibrillary 
acidic protein (GFAP) and nuclear factor kappa-B (NF-κB) in the brain cortex and hippocampus. All these effects 
of silymarin were similar to that of the standard anti-amnestic drug, donepezil.  
CONCLUSION: This study reveals that the ameliorative effect of silymarin on scopolamine-induced dementia in 
rats using the ORT maybe in part mediated by, enhancement of cholinergic activity, anti-oxidant and anti-
inflammatory activities as well as mitigation in brain neurotransmitters and histopathological changes. 
 
 
 
 
 
 
 
 
Introduction 
 
Dementia is characterised by impairments in 
memory and other cognitive abilities [1]. Dementia of 
Alzheimer’s type (DAT) is the most common type of 
dementia. Alzheimer’s disease (AD) is characterised 
by the accumulation of amyloid plaques, 
hyperphosphorylation of tau protein, oxidative stress, 
neuroinflammation leading to neuronal death [2]. 
Deficiency in cholinergic neurotransmission in the 
cerebral cortex and hippocampus accounts for 
dementia in AD patients [3]. 
Object recognition test (ORT), measures non-
spatial working memory in rodents, which is severely 
impaired in patients suffering from DAT [4] [5]. The 
test depends on the spontaneous exploratory 
behaviour of rodents, exposed to the novel 
environment. In comparison to other cognitive 
parameters, ORT does not involve 
reinforcement/response interaction and therefore 
resembles procedures used in humans and have a 
predictive validity [6] [7]. 
Scopolamine, a muscarinic receptor blocker 
that disrupts cholinergic neurotransmission leading to 
memory impairment associated with DAT [8]. 
Scopolamine-induced dementia is a widely used 
animal model for investigating cognitive enhancing 
drugs [9] [10].  
Acetylcholinesterase inhibitors (AChEIs) are 
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the most common drugs used for DAT. However, 
these drugs may cause peripheral cholinergic side 
effects that may restrict their use [11]. Therefore, 
efforts have been directed towards the use of 
alternative anti-amnestic therapies with lower side 
effects [12]. 
Silymarin is a flavonoid isolated from the 
seeds and fruits of Milk Thistle plant. Therapeutically, 
silymarin is used for the treatment of liver diseases 
[13] [14]. It possess anti-cancer [15] [16] anti-apoptotic 
effects [17], in addition to its renoprotective [18] and 
cardioprotective [19] activities. 
Silymarin is a potent anti-oxidant agent, being 
able to cross the blood-brain barrier and exerts a 
neuroprotective effect in various neurodegenerative 
disorders like Parkinson’s disease, stroke, and ageing 
[20] [21] [22]. Although it has been demonstrated that 
silymarin suppresses the accumulation of amyloid 
plaques in an animal model of AD [23], according to 
the author's knowledge its possible memory-
enhancing the effect on scopolamine-induced 
dementia has not been investigated. 
 Therefore, the present study aims to 
elucidate the possible ameliorative effect of silymarin 
on scopolamine-induced dementia using the ORT. 
The study was extended to demonstrate the role of 
cholinergic activity, oxidative stress, 
neuroinflammation, neurotransmitters and 
histopathological changes in the anti-amnestic effect 
of silymarin in demented rats. Donepezil, an AChEI, 
was used as an anti-amnestic standard drug for 
comparison. 
 
 
Material and Methods 
 
Animals 
Male albino Wistar rats weighing 120–150 g 
were used throughout the experiment. They were 
obtained from the animal house colony of the National 
Research Centre (Dokki, Cairo, Egypt) and were 
housed for at least one week in the laboratory room 
before testing under a 12 h alternating light/dark cycle. 
Animals were fed standard laboratory pellets with 
water ad libitum. All animal procedures were 
performed by the Ethics Committee of the National 
Research Centre, Egypt (registration number 17/004) 
which is by the Guide for the Care and Use of 
Laboratory Animals of the National Institutes of Health 
and complied with the guidelines from the Canadian 
Council on Animal Care. 
 
Drugs and chemicals 
Scopolamine hydrobromide was purchased 
from Sigma–Aldrich (MO, USA) and was dissolved in 
saline (0.9% NaCl). Donepezil hydrochloride was 
purchased from Pfizer (Giza, Egypt) and was freshly 
prepared in 1% tween 80 in water. Silymarin was 
supplied by CID pharmaceutical company (Giza, 
Egypt) and was freshly prepared in 1% tween 80 in 
water.  
 
Treatments 
Rats were randomly allocated into 6 groups (8 
rats/group in the object recognition test) as follows: 
group I received saline (0.9% NaCl solution) and 
served as normal while group II received scopolamine 
(16 mg/kg, i.p.) [24] and served as control. Both 
groups received saline for 14 days. Groups III–V rats 
orally received Silymarin (200, 400, 800 mg/kg/day), 
respectively; Group VI rats orally received Donepezil 
(10 mg/kg/day) for 14 consecutive days. Scopolamine 
was administered as a single dose 30 min after the 
last administration in groups II-VI. 
The selection of the doses of silymarin was 
based on the previously published data of Galhardi, 
Mesquita [25]. The dose of donepezil was selected 
according to the previously published data of 
Schreiber, Vivian [26]. 
 
Behavioral test 
Object recognition test 
The test apparatus was designed as 
described by Ennaceur and Delacour [27]. Three days 
before testing, each rat was allowed to explore the 
apparatus for 2 min, while on the testing day, 30 min 
following scopolamine injection, a session of two 
trials, 2-min each was allowed. In the ‘‘sample’’ trial 
(T1), two identical objects were placed in two opposite 
corners of the apparatus. A rat was placed in the 
apparatus and was left to explore these two identical 
objects. After T1, the rat was placed back in its home 
cage, and an inter-trial interval of 1h was given. 
Subsequently, the ‘‘choice’’ trial (T2) was performed. 
In T2, a new object (N) replaced one of the objects 
that were presented in T1; then rats have exposed 
again to two different objects: the familiar (F) and the 
new one (N). 
Exploration was defined as follows: directing 
the nose toward the object at a distance of no more 
than 2 cm and/or touching the object with the nose. 
From this measure, a series of variables were 
then calculated: the total time spent in exploring the 
two identical objects in T1, and that spent in exploring 
the two different objects, F and N in T2. The 
discrimination between F and N in T2 was measured 
by comparing the time spent in exploring the F with 
that spent in exploring the N. DI is the discrimination 
index and represents the difference in exploration time 
expressed as a proportion of the total time spent 
exploring the two objects in T2. DI was then 
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calculated; DI = N-F/N+F. 
 
Brain homogenate preparation for 
biochemical analysis 
Rats were euthanised by decapitation 
following the ORT. The whole brain was carefully 
excised, cortical and hippocampal brain tissues were 
isolated, immediately weighed to avoid any effects 
from drying, and stored at −80°C. 
Cortical and hippocampal brain tissues were 
homogenised (MPW-120; Medical Instruments) in 
10% (w/v) ice-cold phosphate buffer. Then, the 
homogenate was centrifuged using a cooling 
centrifuge (2k15; Sigma/Laborzentrifugen) at 4000 
rpm for 5 min, and the resulting supernatant was used 
for determining the brain contents of 
Acetylcholinesterase activity (AChE), 
malondialdehyde (MDA), and reduced glutathione 
(GSH) in addition to brain neurotransmitters namely 
norepinephrine (NE), dopamine (DA), serotonin (5-
HT), and gamma-aminobutyric acid (GABA) were also 
assessed. 
 
Determination of Acetylcholinesterase 
(AChE) activity 
Acetylcholinesterase activity was determined 
in cortex and hippocampus according to the method 
described [28] [29], the developed colour was read 
spectrophotometrically immediately at 412 nm, and 
the AChE activity was determined in μM per SH group 
(μMSH) from a standard curve. 
 
Determination of lipid peroxidation content 
Lipid peroxidation was assayed by measuring 
cortical and hippocampal MDA content according to 
the method described before [30]. The supernatant 
was read spectrophotometrically at 532 nm, and the 
MDA content is expressed in nanomoles of MDA per 
milligram tissue. 
 
Determination of reduced glutathione 
(GSH) content 
The cortical and hippocampal GSH contents 
were determined according to the method described 
before by Ellman [31]. Calculation of GSH was based 
on a standard glutathione curve and is expressed in 
micromoles of GSH per gram tissue. 
 
Determination of norepinephrine (NE), 
dopamine (DA), and serotonin (5-HT) 
contents 
Brain monoamines, namely, NE, DA, and, 5-
HT, were estimated using HPLC (Agilent 1200 series; 
Agilent Technologies, California, USA) as described 
previously [32]. Cortical and hippocampal contents of 
monoamines are expressed in micrograms of 
monoamine per gram tissue, and were calculated as 
follows: 
Monoamine content (µg/g tissue) = AT/AS × CS × 
dilution factor 
Where: AT = area under the curve for the 
sample, AS = area under the curve for the standard, 
CS = concentration of the standard (µg/mL), and the 
dilution factor = 10. 
 
Determination of Gamma-aminobutyric 
acid (GABA) content 
Cortical and hippocampal GABA content 
(μmol/g tissue) was estimated using HPLC (Agilent 
1200 series; Agilent Technologies, California, USA) 
according to the precolumn phenylisothiocyanate 
derivatisation technique described by Heinrikson and 
Meredith [33]. Cortical and hippocampal contents of 
GABA are expressed in micrograms per gram tissue. 
 
Histopathological examination 
The brain tissues were collected from different 
groups and fixed in 10% neutral buffered formalin then 
processed for obtaining 4 µm paraffin-embedded 
sections. The sections were stained with hematoxylin, 
and eosin stain then examined under the microscope 
[34]. 
 
Immunohistochemistry analysis of GFAP 
and NF-KB p65 
The immunohistochemistry was performed 
according to methods described before [35]. Brain 
tissue sections were deparaffinized in xylene and 
rehydrated in graded alcohol. Hydrogen Peroxide 
Block (Thermo scientific, USA) was added to block the 
endogenous peroxidase activity. Antigen retrieval was 
done by pretreated tissue sections with 10 mM citrate 
in a microwave oven for 10 minutes. Sections were 
incubated for 2 hours with one of the following primary 
antibodies: rabbit anti-GFAP polyclonal antibody 
(ab7260; Abcam, Cambridge, UK) at dilution 1:2000 
and rabbit anti-NF-KB P65 polyclonal antibody 
(ab16502; Abcam, Cambridge, UK) diluted 1 Ug/ml. 
The sections were rinsed with PBS then incubated 
with Goat anti-rabbit IgG H&L (HRP) (ab205718; 
Abcam, Cambridge, UK) for 10 min. The sections 
were rinsed again with PBS. Finally, sections were 
incubated 3, 3’-diaminobenzidine tetrahydrochloride 
(DAB, Sigma). The slides were counterstained with 
haematoxylin then mounted. Primary antibodies were 
replaced by PBS for negative controls. 
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Evaluation of GFAP and NF-κB p65 
immunostaining 
The quantitative immunoreactivity of GFAP 
and NF-κB was evaluated in the brain cortex and 
hippocampus region. In each group, five brain 
sections were examined. The GFAP immunoreactivity 
was analysed in 10 microscopical fields per each 
section under high-power microscopical field (x 400) 
and represented as a percentage of the positively 
stained area. NF-κB positive cells and total cell 
number were counted in 10 microscopical fields per 
each section under high-power microscopical field (x 
400), and the percentage of positively stained cells 
(%) was calculated. The image analysis was 
performed by Leica Qwin 500 Image Analyzer (Leica, 
Cambridge, England). 
 
Statistical Analysis 
Data concerning the ORT, biochemical 
analysis are presented as the mean±SEM for 8 rats 
per group in the behavioural tests and 6 rats per 
group in the biochemical tests. Comparisons between 
more than 2 groups in the ORT and biochemical were 
carried out using one-way analysis of variance 
(ANOVA) followed by Tukey's multiple comparisons 
test, except for the comparison of total exploration 
time in T1 and T2 in the ORT which was carried out 
using 2-way ANOVA followed by Tukey's multiple 
comparisons test and when comparing the exploration 
times of the F and N objects in T2, Student’s t-test 
was used. Immunohistochemical analysis was carried 
out by one-way analysis of variance (ANOVA) 
followed by Newman Keuls multiple comparison tests. 
All analyses utilised GraphPad Prism 6.0 statistical 
package for Windows (GraphPad, San Diego, Calif.). 
Statistical significance was set at P < 0.05. 
 
 
Results 
 
Figure 1a reveals that dementia induced by a 
single i.p. dose of scopolamine (16 mg/kg) 30 min 
before starting T1 in the ORT did not significantly 
affect the total exploration time in T1 and T2. Oral 
administration of silymarin (200, 400, 800 mg/kg), and 
donepezil (10 mg/kg) for 14 consecutive days, before 
scopolamine, did not also show any difference in the 
total exploration time in T1 and T2. During T2, 
Scopolamine-induced demented rats did not reveal 
any significant difference in the exploration time of N 
as compared to their exploration time of F. 
Scopolamine-induced demented rats explored N and 
F objects similarly. Rats pre-treated with silymarin 
(200, 400, 800 mg/kg) were similar to donepezil and 
explored the N object significantly more than F (Figure 
1b). DI indicated that all rats, except scopolamine 
treated rats, discriminated N significantly better than F 
(Figure 1c). 
 
Figure 1: Effect of Silymarin on scopolamine-induced dementia in 
rats using the object recognition test; A) Total exploratory time in T1 
and T2; b) Exploration time of familiar (F) vs the novel object (N) in 
T2; c) Discrimination index (DI). Results are expressed as mean ± 
SEM (n = 8). Statistical analyses were carried out in a) by two-way 
ANOVA followed by Tukey's multiple comparison tests, in b) by 
using Student’s t-test, while in c) by one-way ANOVA followed by 
Tukey’s multiple comparison tests. *Significant difference versus 
correspondent N group at P < 0.05. *Significant difference from the 
normal group at P < 0.05. 
@
Significant difference from control 
(scopolamine) group at P < 0.05 
 
As depicted in Figure 2a and b, demented 
rats showed a significant increase in cortical and 
hippocampal AChE activity to be 14.19 and 11.39 
µmol SH/g/min as compared to normal rats. Pre-
treatment with silymarin (200, 400, 800 mg/kg) 
significantly decreased AChE to be 75.83, 52.36, 
50.74%, respectively in cortical tissue and 52.94, 
43.2, 35.21%, respectively in hippocampal tissue as 
compared to control group. Similarly, donepezil 
administration resulted in significant decrease in 
AChE activity to be 47.71 and 45.23% respectively in 
cortical and hippocampal tissue as compared to 
control group. 
 
Figure 2: Effect of Silymarin on A) cortical and B) hippocampal 
acetylcholinesterase (AChE) activity in scopolamine-induced 
dementia in rats. Results are expressed as mean ± SEM (n = 6). 
Statistical analysis was carried out by one-way ANOVA followed by 
Tukey’s multiple comparison tests. *Significant difference from the 
normal group at P < 0.05. 
@
Significant difference from control 
(scopolamine) group at P < 0.05  
 
Results demonstrated in Figure 3 a, b reveals 
that demented rats increased significantly cortical and 
hippocampal MDA content to be 163.22% and 
149.48% of normal rats, respectively. Preventive 
treatment with silymarin in doses of 200 and 400 and 
800 mg/kg restored cortical MDA content to be 
69.62%, 64.70% and 67.06% of demented rats, 
respectively. Oral administration of silymarin (200 and 
400 mg/kg) restored hippocampal MDA content to be 
62.30% and 63.96% of demented rats, respectively. 
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Silymarin in a dose of 800 mg/kg significantly reduced 
hippocampal MDA content to be 53.68% and 80.25% 
of the scopolamine control group and normal group, 
respectively. Also, Donepezil restored cortical and 
hippocampal MDA content to be 67.37% and 65.02% 
of control rats, respectively. 
 
Figure 3: Effect of Silymarin on A) cortical and B) hippocampal 
reduced malondialdehyde (MDA) activity in scopolamine-induced 
dementia in rats. Results are expressed as mean ± SEM (n = 6). 
Statistical analysis was carried out by one-way ANOVA followed by 
Tukey’s multiple comparison tests. *Significant difference from the 
normal group at P < 0.05. 
@
Significant difference from control 
(scopolamine) group at P < 0.05 
 
Regarding GSH content, Scopolamine 
administration significantly reduced cortical and 
hippocampal GSH contents to be 83.28% and 
88.64%, respectively as compared to normal rats. 
Silymarin administration in doses of 200, 400 and 800 
mg/kg significantly restored cortical GSH contents to 
be 111.69%, 121.53% and 123.77% respectively. 
Preventive administration of silymarin (200 and 400 
mg/kg) restored hippocampal GSH contents to be 
113.83% and 111.17% respectively. The results were 
similar to donepezil as it significantly restored cortical 
GSH contents to be 124.16% and hippocampal GSH  
contents to be 111.55% of the control group (Figure 4 
a, b). 
 
Figure 4: Effect of Silymarin on A) cortical and B) hippocampal 
reduced glutathione (GSH) activity in scopolamine-induced 
dementia in rats. Results are expressed as mean ± SEM (n = 6). 
Statistical analysis was carried out by one-way ANOVA followed by 
Tukey’s multiple comparison tests. *Significant difference from the 
normal group at P < 0.05. 
@
Significant difference from control 
(scopolamine) group at P < 0.05. 
 
The effect of silymarin on cortical and 
hippocampal neurotransmitters in scopolamine-
induced demented rats was summarised in Tables 1 & 
2. Demented and treated rats did not show any 
significant change in cortical and hippocampal NE and 
5-HT contents. Scopolamine-induced demented rats 
showed a significant decrease in cortical and 
hippocampal DA contents to be 58.36% and 22.92% 
of normal rats, respectively. Demented rats also 
significantly reduced cortical and hippocampal GABA 
contents to be 62.69% and 48.41% of normal rats, 
respectively. Silymarin in doses of 400 and 800 mg/kg 
significantly elevated cortical DA content to be 
142.04% and 145.86% of control rats, respectively 
and cortical GABA content to be 145.86% and 
144.52% of control rats, respectively. 
Table 1: Effect of silymarin on cortical neurotransmitters 
content in scopolamine-induced dementia in rats 
Parameters 
Treatment 
Cortical neurotransmitters (µg/g tissue) 
 
Brain Monoamines  
GABA NE DA 5-HT 
Normal 0.95 ± 0.07 2.69
 
± 0.07
@
 0.57 ± 0.03 7.13
 
± 0.29
@
 
Control (scopolamine) 0.65 ± 0.05 1.57± 0.09* 0.59 ± 0.05 4.47 ± 0.46* 
Silymarin 
(200 mg/kg) 
+scopolamine 
0.91 ± 0.18 2.11 ± 0.22 0.65 ± 0.03 5.90 ± 0.40 
Silymarin 
(400 mg/kg) 
+scopolamine 
0.87 ± 0.09 2.23
 
± 0.11
@
 0.64 ± 0.07 6.52
 
± 0.20
@
 
Silymarin 
(800 mg/kg) 
+scopolamine 
0.91 ± 0.05 2.29
 
± 0.18
@
 0.65 ± 0.04 6.46± 0.31
@
 
Donepezil 
(10 mg/kg) 
+ scopolamine 
0.97 ± 0.01 2.35
 
± 0.13
@
 0.64 ± 0.05 6.18± 0.58
@
 
Results are expressed as mean ± SEM (n = 6). Statistical analysis was carried out by one-
way ANOVA followed by Tukey’s multiple comparison tests.*Significant difference from 
normal group at P < 0.05. 
@
Significant difference from control (scopolamine) group at P < 
0.05. 
 
Silymarin in doses of 200, 400, and 800 
mg/kg restored hippocampal DA contents to be 
433.33%, 396.97%, and 472.73% of control rats, 
respectively and restored hippocampal GABA 
contents to be 288.47%, 192.52%, and 217.88% of 
control rats, respectively. Similarly, donepezil restored 
cortical and hippocampal DA contents to be 149.68% 
and 433.33% of control scopolamine group, 
respectively in addition to cortical and hippocampal 
GABA contents to be 138.26% and 177.92% of 
control scopolamine group, respectively. 
Table 2: Effect of silymarin on hippocampal neurotransmitters 
content in scopolamine-induced dementia in rats 
Parameters 
Treatment 
Hippocampal Neurotransmitters (µg/g tissue) 
Brain Monoamines  
GABA NE DA 5-HT 
Normal 0.67±0.04 1.44*±0.06 0.64±0.03 11.32
@
±0.32 
Control (scopolamine) 0.65±0.06 0.33
@
±0.02 0.71±0.04 5.48*±0.15 
Silymarin 
(200 mg/kg) 
+scopolamine 
0.63±0.05 1.43
@
±0.06 0.70±0.06 12.52
@
±1.11 
Silymarin 
(400 mg/kg) 
+scopolamine 
0.65±0.05 1.31
@
±0.07 0.65±0.06 10.55
@
±0.85 
Silymarin 
(800 mg/kg) 
+scopolamine 
0.63±0.04 1.56
*@
±0.06 0.69±0.04 11.94
@
±0.52 
Donepezil 
(10 mg/kg) 
+ scopolamine 
0.63±0.04 1.43
@
±0.06 0.73±0.01 9.75
@
±0.55 
Results are expressed as mean ± SEM (n = 6). Statistical analysis was carried out by one-
way ANOVA followed by Tukey’s multiple comparison tests. *Significant difference from 
the normal group at P < 0.05. 
@
Significant difference from control (scopolamine) group at 
P <0.05. 
The control group revealed normal 
histological finding (Figure 5A, 6A). The scopolamine 
treated group showed marked thickening of the 
endothelium lining blood vessels with clear 
perivascular oedema, degenerative neuronal changes 
in the form of central chromatolysis and neuronal 
swelling in the brain cortex. Moreover, some neuron 
was shrunken with pyknotic or lytic nuclei (Fig. 5B) 
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and neuronophagia. In the hippocampus region, the 
scopolamine treated group showed thickening of the 
endothelium lining blood vessels with perivascular and 
pericellular oedema; some pyramidal cells degenerate 
with neuronophagia and gliosis (Fig. 6B).  
 
Figure 5: Histopathological changes in the brain cortex of the 
different treated groups (H&E x400). A. Normal control group 
showing normal histological finding; B. Scopolamine treated group 
showing marked neuronal degeneration (arrow) with neurophagia 
and gliosis; C. Silymarin (200 mg/kg) + scopolamine showing 
moderate neuronal degeneration with neurophagia (arrow); D. 
Silymarin (400 mg/kg) + scopolamine showing moderate 
perivascular edema (arrow) with mild neuronal degeneration; E. 
Silymarin (800 mg/kg) + scopolamine showing slight perivascular 
edema (arrow); F. Donepezil (10 mg/kg)+ scopolamine group 
showing mild neuronal degeneration (arrow) and neurophagia  
 
Swelling of the pyramidal cells was also 
observed. The previous described histopathological 
changes were markedly attenuated in all treated 
group with donepezil (Fig. 5F, 6F) and silymarin in a 
dose-dependent manner (Fig. 5 & 6 C, D, E) 
compared to the scopolamine treated group. 
Figure 9 summarised the results of 
immunohistochemical evaluation of GFAP and NF-kB 
expression in the different experimental groups. In 
GFAP immunostaining, the astroglia cell in the control 
group appeared with thin processes and lightly 
stained cell body (Figure 7A). While the astroglia cell 
in the scopolamine treated group appeared with thick, 
dense processes and darkly stained cell body (Figure 
7B). The scopolamine treated group showed a 
significant increase in GFAP immunostaining 
comparing to control group (Figure 7B). The 
Donepezil (Figure 7F) and silymarin-treated groups 
(Figure 7C, D, E) showed a significant reduction in 
GFAP immunostaining compared to the scopolamine 
treated group (Figure 9A). 
 
Figure 6: Histopathological changes in the hippocampus of the 
different treated groups (H&E X400). A. Normal control group 
showing normal histological picture; B. Scopolamine treated group 
showing marked degeneration of pyramidal cells (arrow) with 
neuronophagia and pericellular edema; C. Silymarin (200 mg/kg) + 
scopolamine showing mild degeneration of pyramidal cells (arrow); 
D. Silymarin (400 mg/kg) + scopolamine showing thickening of the 
endothelial lining blood vessels with perivascular edema (arrow); E. 
Silymarin (800 mg/kg) + scopolamine showing normal histological 
finding.; F. Donepezil (10 mg/kg) + scopolamine showing mild 
pyramidal cells swelling 
 
NF-kB immunostaining was detected in 
cytoplasm and or nucleus of the neuron and glial cells. 
The cytoplasmic staining of the cells represented in 
the active form of NF-kB. While nuclear staining of the 
cells represented the active form of the NF-kB. So, the 
nuclear-stained cells were only counted as the 
immunopositive cells. The percentage of 
immunopositive cells for NF-kB immunostaining of the 
scopolamine treated group (Figure 8B) was 
significantly elevated than the control group (Figure 
8A). The donepezil (Figure 8F) and silymarin-treated 
groups (Figure 8 C, D, E) showed a significant 
reduction in the percentage of NF-kB immunopositive 
stained cells in dose-dependent manner compared to 
the scopolamine treated group (Fig. 9B).  
 
 
Discussion 
 
This study adds new information on the 
memory-enhancing the effect of silymarin (200, 400, 
800 mg/kg), which was similar to donepezil in 
scopolamine-induced demented rats using the ORT. 
To the best of the authors’ knowledge, this is the first 
report that highlighted the involvement of cholinergic 
activity, oxidative stress biomarkers namely (MDA and 
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GSH), inflammatory biomarkers such as NF-KB and 
GFAP, brain neurotransmitters as well as 
histopathological changes in the anti-amnestic effect 
of silymarin in scopolamine-induced demented rats 
using the ORT. 
 
Figure 7: Representative GFAP immunohistochemistry in the 
hippocampus region of different treated groups (X400). A. Control 
group showing weak immunostaining of astroglia cells (arrow); B. 
Scopolamine treated group showing strong immunostaining of 
astroglia cells with thick, dense processes and darkly stained cell 
body (arrow); C. Silymarin (200 mg/kg) + scopolamine and D. 
Silymarin (400 mg/kg) + scopolamine showing moderate 
immunostaining of astroglia cells (arrow); E. Silymarin (800 mg/kg) 
+ scopolamine showing thin processes and lightly stained cell body 
of astroglia cells (arrow); F. Donepezil (10 mg/kg) + scopolamine 
group showing reduction in the immunostaining of astroglia cells 
(arrow) 
 
In this study, scopolamine-induced demented 
rats impaired recognition memory in the ORT, as 
demented rats explored both F and N objects similarly 
and were not able to discriminate between both 
objects. These results are in harmony with prior 
studies [36] [37]. 
Silymarin-treated rats reversed scopolamine-
induced non-spatial working memory impairment in 
the ORT as they were able to discriminate between 
the F and N objects and increased the time spent in 
identifying the N object concerning the F object. 
These effects are similar to the standard drug, 
donepezil. 
Since the total exploration time within T1 and 
T2 were similar in demented, silymarin and donepezil-
treated rats, therefore it can be deduced that 
attentional and sensorimotor activities did not 
influence rats’ performance in the ORT. This indicates 
that memory enhancing effects of silymarin and 
donepezil was independent on non-specific factors of 
rats. 
 
Figure 8: Representative NF-kB immunohistochemistry in the brain 
cortex of different treated groups ( x 400). A. Control group showing 
very weak nuclear reaction; B. Scopolamine treated group showing 
strong and numerous nuclear staining (arrow); C. Silymarin (200 
mg/kg) + scopolamine and D. Scopolamine + S400 showing 
moderate nuclear immunoreaction (arrow); E. Scopolamine + S800 
showing weak nuclear immunostaining (arrow); F. Donepezil treated 
group showing reduction in the immunopositive cells (arrow) 
 
In this work, donepezil, which is a potent 
AChEI, administered orally at 10mg/kg/day for 14 
consecutive days before scopolamine ameliorated 
cholinergic deficits, oxidative stress, inflammation, and 
histopathological changes in the brain of scopolamine-
induced demented rats. These findings are in 
concordance with prior studies [38][39] and 
emphasize the effectiveness of donepezil as standard 
anti-amnestic agent for screening novel therapeutics 
for treating cognitive deficit. 
 
Figure 9: Immunohistochemical evaluation of GFAP and NF-kB 
expression in the different treated groups. A. The bar chart of GFAP 
immunostaining expressed as area %. B. The bar chart of NF-kB 
immunostaining expressed as the percentage of positively stained 
cells. Statistical analysis was carried out by one-way ANOVA 
followed by Newman Keuls multiple comparison tests. *Significant 
difference from the normal group at P < 0.05. 
@
Significant difference 
from control (scopolamine) group at P < 0.05 
 
In this study, Scopolamine-induced dementia 
resulted in cholinergic system dysfunction as 
evidenced by elevation in AChE activity, an important 
enzyme which hydrolyses ACh, an essential 
neurotransmitter involved in learning and memory. 
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This finding is in line with prior studies [40] [41].  
Preventive treatment with silymarin and 
donepezil decreased cortical and hippocampal AChE 
activity, indicating that silymarin might have 
ameliorated cognitive, cognitive deficit in the ORT 
partly via enhancing cholinergic neurotransmission. 
Prior studies have reported that silymarin has also 
protected against high fat diet-induced dementia and 
manganese-induced neurotoxicity via restoration of 
AChE activity [42] [43]. 
Oxidative stress has been implicated in the 
pathogenesis of DAT. This is apparent in the current 
investigation as scopolamine-induced dementia 
resulted in the elevation of cortical and hippocampal 
MDA content, the final product of lipid peroxidation 
and subsequent reduction of the endogenous anti-
oxidant namely GSH, due to elevated Reactive 
Oxygen Species (ROS). This finding is inconsistent 
with prior studies [44] [45] and implies that 
scopolamine associated oxidative stress accounts for 
memory impairment in the study. 
Preventive treatment with silymarin reversed 
scopolamine associated oxidative stress to be similar 
to that of donepezil as it reduced cortical and 
hippocampal MDA content, lipid peroxides formation 
by elevating the ROS scavenging activity of cortical 
and hippocampal GSH content. This reveals that 
ameliorative effect of silymarin on scopolamine-
induced dementia in rats may be partly due to its 
antioxidant activity. Several studies have also 
demonstrated the neuroprotective of silymarin against 
oxidative stress associated with experimentally-
induced Parkinson’s disease and cerebral ischemia 
[46] [47]. 
Neurotransmitters such as GABA and 
dopamine have a greater impact on memory retrieval 
and consolidation than 5-HT and NE [48]. GABAergic 
and DAergic deficits contribute to memory impairment 
in patients suffering from AD [49] [50]. 
In line with this notion, scopolamine-induced 
pathological changes were coupled with deficits in 
cortical and hippocampal GABA and dopamine 
contents. This finding is inconsistent with that of [51] 
[52]  
Pretreatment with silymarin restored GABA 
and DA contents to be similar to donepezil. This 
implies that anti-oxidant effect of silymarin may 
contribute to the preservation of neurotransmitters, 
and thereby memory-enhancing effect in amnestic 
rats. Previous studies reported that silymarin restored 
DA content in 1-Methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP)-induced Parkinson’s 
disease and stress-induced depression in mice [53] 
[54]. 
As mentioned before, elevated AChE activity 
in DAT aggravates the formation of Aβ plaques which 
in turn activates astrocytes and upregulate GFAP, an 
indicator of neuroinflammation [55] [56]. 
Scopolamine-induced dementia in this work 
showed an elevation in hippocampal and cortical 
protein expression of GFAP when compared to 
normal rats. This finding is in harmony with a prior 
study [57] and implies that scopolamine upregulated 
inflammatory cascade via astrocytic activation.  
Silymarin administration counteracted 
scopolamine-induced elevation in protein expression 
of GFAP, by suppressing astrocyte activation. This 
reveals that inhibition of astrocytic activation might 
have resulted from suppression of inflammatory 
cascade and oxidative stress. 
Oxidative stress contributes to the elevation of 
ROS which results in activation of NF-κB, a 
transcription factor responsible for regulation of pro-
inflammatory genes such as, cytokines and 
chemokines [58] [59] [60]. 
In this work, scopolamine-induced dementia 
increased protein expression of NF-κB in the brain 
cortex and hippocampus, indicating that elevated 
inflammatory response resulting from oxidative stress 
might account for cognitive deficit in amnestic rats.  
Prior treatment with silymarin combated the 
elevated protein expression of NF-κB in the brain 
cortex and hippocampus of demented rats; this 
suggests that silymarin ameliorated cognitive deficit 
via suppression of inflammatory cascade probably 
through its anti-oxidant effect in demented rats. This 
finding is inconsistent with other studies [61] [62] [63] 
[64]. 
It can be concluded that the memory-
enhancing the effect of silymarin in scopolamine-
induced demented rats using the ORT may be partly 
mediated by, attenuating cholinergic deficits, anti-
oxidant and anti-inflammatory effects as well as 
amelioration in DAergic, GABAergic 
neurotransmission and histopathological changes. 
Further pre-clinical studies are warranted to 
investigate other mechanisms that may underlie the 
anti-amnestic effect of silymarin. Clinical studies are 
needed to address the validity of silymarin to prevent 
or slow down the progression of DAT. 
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